AIDS-related Kaposi Sarcoma Clinical Trial
Official title:
A Phase II Trial of Topical Halofuginone in Patients With HIV Related Kaposi's Sarcoma
Verified date | June 2013 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This phase II trial studies how well halofuginone hydrobromide works in treating patients with human immunodeficiency virus (HIV)-related Kaposi's sarcoma. Halofuginone hydrobromide ointment may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.
Status | Completed |
Enrollment | 30 |
Est. completion date | |
Est. primary completion date | December 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - Biopsy-proven Kaposi's sarcoma with at least 14 cutaneous lesions, 12 of which are measurable in two dimensions and can serve as marker lesions; each of the 14 lesions must measure a minimum of 0.5 cm in diameter, so that a 4 mm punch biopsy will be entirely composed of Kaposi's sarcoma - Serologic documentation of HIV infection by any of the Food and Drug Administration (FDA) approved tests - Karnofsky performance status >= 60% - Hemoglobin >= 8 g/dl - Absolute neutrophil count >= 750 cells/mm^3 - Platelet count >= 75,000/mm^3 - Creatinine < 1.5 times the upper limit of normal or creatinine clearance >= 60 mL/min - Total bilirubin should be =< 1.5 x upper limit of normal (ULN); if, however, the elevated bilirubin is felt to be secondary to indinavir therapy, patients will be allowed to enroll on protocol if the total bilirubin is =< 3.5 mg/dl provided that the direct bilirubin is normal - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x the upper limit of normal - Life expectancy >= 3 months - Ability and willingness to give informed consent; patients who are younger than 18 years of age will require the consent of a parent or guardian. - All women of childbearing potential must have a negative serum b human chorionic gonadotropin (HCG) within 72 hours prior to study entry and must practice adequate birth control to prevent pregnancy while receiving treatment and for three months after treatment is discontinued - Patients must, in the opinion of the investigator, be capable of complying with the protocol - Patients receiving antiretroviral therapy must be on a stable regimen for at least 12 weeks prior to study entry without showing evidence of ongoing Kaposi's sarcoma (KS) regression (ie, less than 25% decrease in the size, number or nodularity of KS lesions in the opinion of the investigator); patients may receive any FDA approved antiretroviral therapy or agents available through a treatment IND; concurrent treatment with highly active antiretroviral therapy should be strongly encouraged, in accordance with DHHS guidelines (http://www.aids-ed.org/pdfs/adult_2-4-02.pdf) but will not be required for participation Exclusion Criteria: - Concurrent, acute, active, untreated opportunistic infection other than oral thrush or genital herpes within 14 days of enrollment - Known active visceral Kaposi's sarcoma or symptomatic Kaposi's sarcoma-related edema that interferes with function or requires cytotoxic therapy - Concurrent neoplasia requiring cytotoxic therapy - Acute treatment for an infection (other than oral thrush or genital herpes) or other serious medical illness within 14 days of study entry - Anti-neoplastic treatment for Kaposi's sarcoma (including chemotherapy, radiation therapy, local therapy, biological therapy, or investigational therapy) within four weeks of study entry - Previous local therapy of any KS-indicator lesion within 60 days unless the lesion has clearly progressed since treatment - Corticosteroid treatment, other than replacement doses - Use of investigational agents other than antiretroviral drugs available under expanded access or compassionate use protocols - Pregnant or breast feeding females are excluded from participation in this study since the effects of halofuginone on an unborn or young child are unknown and may potentially be toxic |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | AIDS - Associated Malignancies Clinical Trials Consortium | Rockville | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response rate | McNemar's chi-square test will be used to compare vehicle control and halofuginone with respect to response rates. | Up to 30 days | No |
Primary | Safety of topical halofuginone as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 | McNemar's chi-square test will be used to compare the two treatments with respect to the incidence of specific adverse events. | Up to 30 days after completion of treatment | Yes |
Secondary | Change in MMP-2 and collagen type I levels | From baseline to 4 weeks | No | |
Secondary | Change in MMP-2 and collagen type I levels | Changes from baseline in MMP-2 and Collagen type I for halofuginone and vehicle control lesions will be compared using the Wilcoxon rank sum test. | From baseline to 12 weeks | No |
Secondary | Relationship of CD4, CD8, HIV viral load and HHV-8 viral load on response | Logistic regression analysis will be used. | Up to 30 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03596918 -
Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
|
||
Not yet recruiting |
NCT05567601 -
Doxil/Caelyx BE Study
|
Phase 1 | |
Terminated |
NCT04893018 -
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
|
Phase 1 | |
Terminated |
NCT00020683 -
A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma
|
Phase 2 | |
Completed |
NCT00003350 -
Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
|
Phase 3 | |
Not yet recruiting |
NCT05411237 -
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
|
Phase 3 | |
Active, not recruiting |
NCT05510973 -
Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi
|
N/A | |
Recruiting |
NCT05510908 -
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
|
||
Withdrawn |
NCT02137564 -
Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
|
Phase 2 | |
Completed |
NCT01016730 -
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
|
Phase 1 | |
Withdrawn |
NCT00521092 -
Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
|
Phase 2 | |
Completed |
NCT01057121 -
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
|
Phase 1/Phase 2 |